Elucid Bioimaging, formerly dba VascuVis Inc, works in medical imaging using its patented, multi-modality, Computer-Aided Phenotyping (CAP) Platform, first in cardiology and oncology, with potential beyond. With ties of Rutgers, the company's vascuCAP platform is used in the diagnosis of vascular problems; it quantitatively and objectively analyzes the verifiable biophysical hallmarks predictive of atherosclerotic plaque instability. Elucid Bioimaging, Inc. is building the Computer-Aided Phenotyping (CAP) Platform, a cutting-edge bioimaging system that can reduce the rates of misclassification that lead to increased medical costs and over- and under-diagnosis in cardiology and oncology. Elucid's lungCAP platform is used in the diagnosis of lung cancer; it analyzes the verifiable biophysical hallmarks predictive of malignancy. The company provides analytical services, software development, outsourcing, and product development. As a service provider, the company engages with clients and partners in the development of technology, strategy, and cross-stakeholder solutions to meet these needs. As a research organization, it acts as prime or sub on grants, cooperative agreements, and research contracts.
